About 75% of the members of panels setting definitions and diagnosis guidelines for 14 diseases had connections to drugmakers marketing or developing products for the same conditions, a study published in PLOS Medicine found. Members of 12 panels disclosed ties to more than one company, and only the panel changing the definition of type 2 diabetes disclosed no financial ties, researchers found.

Related Summaries